EUVIMEDEUVIMED entdecken
Crossref

200.09 DOACS vs Warfarin After TAVR in Atrial Fibrillation: A Global Propensity-Matched Outcomes Study

Ibrahim Halil Inanc, Asigul Yimit, Mohamed Darwish, Fulden Akyuz Inanc, Cagri Aksu, Safina Irani, Daniel Ratliff

JACC: Cardiovascular Interventions · 2026-03 · 19 (5) · S27

DOI: 10.1016/j.jcin.2026.01.090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2026-03. Verfasst von Ibrahim Halil Inanc und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Inanc, I. H., Yimit, A., Darwish, M., Inanc, F. A., Aksu, C., Irani, S., & Ratliff, D. (2026). 200.09 DOACS vs Warfarin After TAVR in Atrial Fibrillation: A Global Propensity-Matched Outcomes Study. JACC: Cardiovascular Interventions, 19(5), S27. https://doi.org/10.1016/j.jcin.2026.01.090

Vancouver

Inanc IH, Yimit A, Darwish M, Inanc FA, Aksu C, Irani S, et al. 200.09 DOACS vs Warfarin After TAVR in Atrial Fibrillation: A Global Propensity-Matched Outcomes Study. JACC: Cardiovascular Interventions. 2026;19(5):S27. doi:10.1016/j.jcin.2026.01.090

BibTeX
@article{Inanc2026,
  author = {Inanc, Ibrahim Halil and Yimit, Asigul and Darwish, Mohamed and Inanc, Fulden Akyuz and Aksu, Cagri and Irani, Safina and Ratliff, Daniel},
  title = {200.09 DOACS vs Warfarin After TAVR in Atrial Fibrillation: A Global Propensity-Matched Outcomes Study},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  volume = {19},
  number = {5},
  pages = {S27},
  doi = {10.1016/j.jcin.2026.01.090}
}
Kostenlos starten →